Yes — in a large new study of more than 256,000 adults with prediabetes and obesity, the glp-1 drugs prevent type 2 diabetes study 2026 found that people taking GLP-1 medications had a 31% lower risk of developing full type 2 diabetes over three years than people taking metformin, and they were also 50% more likely to see their blood sugar return to normal. But before anyone gets carried away, there is an important catch: this was an observational study of medical records, not a randomised trial, and the full peer-reviewed paper has not been published yet.
Still, the numbers are hard to ignore. When a study covers a quarter of a million people and the differences show up across diabetes, heart attacks, strokes and even deaths from any cause, doctors pay attention — and so should anyone living with prediabetes. So what did the researchers actually find, how does it compare with the standard treatment, and what does it mean for you? Let us walk through it slowly, in plain English, with no hype and no medical advice.
What the glp-1 drugs prevent type 2 diabetes study 2026 Actually Found
The study, reported by Reuters Health Rounds on 4 November 2026, looked back at the medical records of more than 256,000 adults who had both prediabetes and obesity. About half of them were taking a GLP-1 medication — semaglutide, tirzepatide, liraglutide or dulaglutide — and the other half were taking metformin, the long-standing first-choice medicine for blood sugar control. The researchers then followed both groups for three years and compared what happened to them.
The headline result is the one most people will remember: over that three-year period, the GLP-1 group had a 31% lower risk of developing full type 2 diabetes than the metformin group. In other words, for every hundred people who might have crossed the line into diabetes on metformin, noticeably fewer crossed it on a GLP-1 drug. That is not a small gap. It is the kind of difference that changes how doctors think about early treatment.
But the diabetes result was only part of the story. The GLP-1 group also had a 50% higher chance of reversing their high blood sugar back to normal levels — a genuine reversal of prediabetes, not just a slowing down of the disease. And perhaps most strikingly, they had a 41% lower risk of death from any cause during the three years. A 41% gap in deaths is enormous, and it is the figure that will probably get the most discussion when the study is formally presented at the American Heart Association Scientific Sessions 2026 in Chicago, from 6 to 9 November.
The study was led by Dr. Vinicius de Sousa Barzon Serra of the Mayo Clinic in Scottsdale, Arizona, a name worth remembering because his team did the painstaking work of matching and comparing these two very large groups of real patients. Real-world records like these are messy — people miss doses, change doctors, and develop other illnesses — but they also show what happens outside the neat, controlled world of a clinical trial, which is why doctors take them seriously.
GLP-1 vs Metformin: How the Two Treatments Compare
To understand why these results matter, it helps to know what metformin is. For decades, metformin has been the standard first medicine offered to people with prediabetes and early type 2 diabetes. It is cheap, it has been used for a very long time, doctors know its safety profile inside out, and it works reasonably well at keeping blood sugar down. Nobody in this study is suggesting that metformin is useless — far from it. The question the researchers asked was simpler: in the real world, do the newer GLP-1 drugs do a better job than the old standard?
GLP-1 medications work in a very different way. They mimic a gut hormone that tells the pancreas to release insulin when blood sugar rises, slows down how quickly the stomach empties, and signals the brain that you feel full. The result is usually lower blood sugar, less appetite, and meaningful weight loss — and weight loss on its own is one of the most powerful tools against prediabetes, because carrying extra weight makes the body's cells less responsive to insulin.
That difference in mechanism may help explain the gap in results. Metformin mainly reduces the amount of sugar the liver releases into the blood. GLP-1 drugs attack the problem from several directions at once: blood sugar, appetite, weight, and possibly the health of blood vessels themselves. When a treatment helps on several fronts, the benefits tend to show up in several places — which is exactly what this study observed.
The numbers, side by side
Here is the cleanest way to see the comparison. Every figure below is the difference for the GLP-1 group compared with the metformin group, over three years:
| Outcome over 3 years | GLP-1 group vs metformin group |
|---|---|
| Chance of blood sugar returning to normal | 50% higher |
| Risk of developing type 2 diabetes | 31% lower |
| Risk of death from any cause | 41% lower |
| Heart attacks | 15% fewer |
| Strokes | 20% fewer |
| Cases of heart failure | 25% fewer |
| Cases of atrial fibrillation | 8% fewer |
Read that table slowly, because it tells a bigger story than diabetes alone. This was not a study about one number on a blood test. It was a study about hearts, brains and lives — and on every single measure, the GLP-1 group came out ahead.
glp-1 drugs prevent type 2 diabetes study 2026: What the Numbers Mean in Plain English
Percentages can sound impressive without meaning much, so let us translate them into everyday language. A 31% lower risk of diabetes does not mean that 31 out of every 100 people were saved from diabetes. It means that whatever your personal risk of developing diabetes was on metformin, it was roughly a third lower on a GLP-1 drug. For someone whose risk was already high — a person with obesity, a family history of diabetes, and blood sugar creeping upward year after year — a third less risk is a genuinely big deal.
The 50% higher chance of reversal is perhaps the most hopeful figure of all. Prediabetes is often described as a warning light on the dashboard, and for years the standard advice has been diet, exercise, and watchful waiting. What this study suggests is that, for many people, the warning light can actually switch off — blood sugar can come back into the normal range and stay there. That matters because once blood sugar is normal again, the slow damage that high sugar does to eyes, kidneys, nerves and blood vessels also slows down.
And then there is the 41% lower risk of death from any cause. Doctors are usually cautious about a number that large, because death has many causes and a single medicine rarely moves all of them at once. The honest interpretation is that the figure probably reflects a combination of things — fewer heart attacks and strokes, healthier weight, better blood sugar — adding up over three years in a very large group of people. It is a strong signal, but it is a signal that needs confirming in a randomised trial before anyone calls it settled science.
One more thing worth saying plainly: these results describe averages across more than 256,000 people. They do not predict what will happen to any one person. Some people on GLP-1 drugs still developed diabetes. Some people on metformin did perfectly well. Averages guide doctors; they do not decide individual fates. That is why the researchers themselves, and every careful doctor reading this study, will say the same thing: talk to your own doctor before changing any medication.
Prediabetes Reversal: What a 50% Higher Chance Really Means
Prediabetes sounds mild. It is not. It means your blood sugar is higher than normal but not yet high enough to be called diabetes — and while you sit in that in-between zone, damage is quietly happening. Blood vessels stiffen, nerves get irritated, and the risk of a heart attack starts climbing years before any diabetes diagnosis appears. That is why doctors now treat prediabetes as a serious condition in its own right, not just a "watch it" situation.
Reversal, in this study, meant blood sugar measurements coming back into the normal range. That is a meaningful milestone, and the fact that the GLP-1 group reached it half as often again as the metformin group tells us something important about how powerful weight loss and appetite control can be. When people eat less, lose weight, and keep their blood sugar steadier day after day, the body's insulin system gets a chance to recover — sometimes dramatically.
But reversal is not the same as a cure, and it is not a finish line you cross once and forget about. Blood sugar can rise again if weight returns or healthy habits slip. The people in this study who reversed their prediabetes still need regular check-ups, still need to watch their diet and activity, and still need their doctor's guidance. Think of reversal as remission — a wonderful, hard-won state that needs protecting.
It is also worth remembering that medicines were only part of the picture. The study compared two groups of people taking different drugs; it did not test diet and exercise on their own. Everything we already know about lifestyle still applies: walking every day, eating more vegetables and whole grains, cutting back on sugary drinks, sleeping well, and keeping weight down all help blood sugar enormously. A medicine can make those habits easier — less hunger makes smaller portions feel natural — but it cannot replace them. If you want a useful mental image, think of the drug as a strong wind at your back while you walk uphill: it helps a lot, but you still have to walk.
Who might this matter most for?
The study focused on adults who had both prediabetes and obesity, so its results speak most directly to that group. If you have prediabetes but are not carrying much extra weight, or if your blood sugar is only slightly above normal, these findings may not apply to you in the same way. Age, other health conditions, family history, and the medicines you already take all shape the decision. This is exactly the kind of conversation that belongs in a doctor's office, with your own test results on the table — not in a blog post, and not on social media.
GLP-1 Heart Benefits Go Beyond Blood Sugar
Look again at the heart figures, because they are easy to rush past: 15% fewer heart attacks, 20% fewer strokes, 25% fewer cases of heart failure, and 8% fewer cases of atrial fibrillation — an irregular heartbeat that raises the risk of stroke. These are not diabetes numbers. They are heart numbers. And they suggest that GLP-1 drugs may protect the heart through more than just lower blood sugar.
Scientists have been building this picture for a few years now. Earlier research on GLP-1 drugs and surgery complications, for example, hinted that these medicines change how the body handles stress and inflammation, not just sugar. Separate studies have linked everyday factors such as research linking everyday noise to heart risk to cardiovascular problems, reminding us that the heart responds to the whole environment of a person's life. And the troubling finding that rural heart attack deaths are rising faster than in cities shows how much heart health depends on early, effective treatment reaching people in time.
The likely explanation is a mix of effects. Weight loss takes strain off the heart. Lower blood sugar means less damage to blood vessel walls. Less appetite often means less salt and less unhealthy fat in the diet. And there is growing evidence that GLP-1 drugs reduce inflammation inside blood vessels directly. Add those together over three years, in a quarter of a million people, and you get fewer heart attacks and strokes. It is a tidy story — but remember, this study can show that these things happened together, not prove that one caused the other. That is the nature of observational research, and it is why the caveat matters so much.
What about the heart rhythm finding?
The 8% reduction in atrial fibrillation is the smallest figure in the table, and that is worth noting honestly. Atrial fibrillation is a chaotic, irregular heartbeat, and it is common in people with obesity and high blood pressure. An 8% difference is modest, but it points in the same direction as everything else in the study. When seven different outcomes all point the same way, researchers start to trust the pattern — even if one or two of the individual numbers are modest.
Why This Study Matters During American Diabetes Month
November is American Diabetes Month, and the timing of this study is no accident — the researchers are presenting their findings at the American Heart Association Scientific Sessions 2026 in Chicago, from 6 to 9 November, right in the middle of a month dedicated to diabetes awareness. That timing matters, because the scale of prediabetes in the United States is genuinely shocking.
According to CDC's figures on prediabetes in the United States, about 98 million American adults — roughly 38% of the adult population — have prediabetes, and more than 80% of them do not know it. Read that again: nearly four in ten adults are walking around with blood sugar above normal, and four out of five of them have no idea. Most will find out only when a routine blood test flags it, or worse, when diabetes itself is diagnosed.
That is why a study like this one gets so much attention. If a treatment can cut the risk of diabetes by nearly a third and help half as many people again return their blood sugar to normal, the potential benefit across 98 million people is enormous. But the gap between a study result and real-world benefit is exactly where the hard questions live: who can get these medicines, who can afford them, and who even knows they have prediabetes in the first place?
Those questions do not have easy answers, and this article will not pretend otherwise. GLP-1 drugs are expensive in the United States, insurance coverage varies widely, and they are not currently approved specifically for prediabetes — they are prescribed for type 2 diabetes and, in some cases, for weight management. Nobody should read this study as a reason to demand a prescription or to stop taking metformin. The right next step for most people is far simpler and far less dramatic: get your blood sugar tested, know your number, and talk it through with your doctor.
What the Study Cannot Tell Us Yet
Honesty requires a full, clear-eyed look at the limits of this research — and there are several. The first and biggest is that the study is observational. The researchers reviewed medical records after the fact; they did not randomly assign people to GLP-1 drugs or metformin. That means the two groups might have differed in ways the records cannot fully capture. Perhaps the people prescribed GLP-1 drugs were more motivated, or had better access to healthcare, or saw their doctors more often. Researchers try to adjust for these differences, but adjustment is never perfect.
The second limit is that the full peer-reviewed publication is still pending. The findings were reported by Reuters Health Rounds on 4 November 2026 ahead of the conference presentation, which is normal for big medical meetings — but it means independent experts have not yet had the chance to examine the methods in full detail. Numbers can shift slightly between a conference presentation and a published paper, and sometimes the interpretation changes too. The Reuters Health Rounds report on the study is the source for every figure in this article, and it is worth reading directly if you want the original reporting.
Third, three years is a good length of follow-up, but diabetes is a lifelong condition. We do not yet know whether the advantage of GLP-1 drugs grows, holds steady, or fades over five or ten years. We also do not know from this study how long people stayed on the drugs, how many stopped because of side effects, or what happened after they stopped. Those are the questions a longer study — ideally a randomised trial — will need to answer.
Finally, the study did not compare GLP-1 drugs with lifestyle change alone, and it did not test whether combining a GLP-1 drug with intensive diet and exercise works better than either approach on its own. Common sense says the combination would be powerful, but common sense is not evidence. What we can say with confidence is narrower and still important: among people with prediabetes and obesity who were already taking one of these two medicines, those on GLP-1 drugs fared better on every measure the researchers tracked.
That is why the glp-1 drugs prevent type 2 diabetes study 2026 should be read as a strong, hopeful signal — not as a final verdict. Science works in steps: a big observational study points the way, and then randomised trials confirm, refine, or sometimes overturn what it found. This study has done its job by pointing the way very clearly. The next steps belong to the researchers.
A note on safety and side effects
This article has focused on benefits, but no honest discussion of a medicine can ignore side effects. GLP-1 drugs are known to cause nausea, reduced appetite, and stomach discomfort in some people, and they are not suitable for everyone. This study did not set out to measure side effects in detail, so nothing in its results should be taken as a safety verdict. If you are already taking a GLP-1 drug and something feels wrong, tell your doctor — do not quietly stop the medicine and do not quietly carry on. And if you are thinking about starting one, the conversation about benefits, risks, costs, and alternatives is one only your own doctor can have with you properly.
What You Can Do Right Now
You do not need a prescription to take the single most useful step this study points to: find out where your blood sugar stands. If you have not had it tested in the last year or two — especially if you carry extra weight, have a parent or sibling with diabetes, or had high blood sugar in a past pregnancy — ask your doctor for a test. It is a simple blood draw, and knowing your number changes everything about the conversation that follows.
While you wait for that appointment, the everyday habits that help blood sugar are the same ones doctors have recommended for years, and they work whether or not you ever take a medicine:
- Walk every day, even if it is just thirty minutes around your neighbourhood — brisk walking is one of the most underrated diabetes-prevention tools we have.
- Build your plate around vegetables, whole grains and lean protein, and keep sugary drinks and heavily processed snacks as the exception rather than the rule.
- Watch portion sizes, especially in the evening, when most of us eat more than we need without noticing.
- Sleep seven to eight hours where you can; poor sleep makes blood sugar harder to control the next day.
- Keep your weight trending gently downward if your doctor has advised it — even a modest loss makes a measurable difference to insulin sensitivity.
- Keep every follow-up appointment, even when you feel fine, because prediabetes is silent and only testing reveals it.
None of this is glamorous, and none of it makes headlines the way a 31% risk reduction does. But it is the foundation everything else rests on. Medicines can help enormously, as this study shows — but they help most in a body that is already being looked after. For more context on how GLP-1 drugs have been studied in other settings, you can read our earlier piece on earlier research on GLP-1 drugs and surgery complications, which shows how widely these medicines are now being examined.
Frequently Asked Questions
Do GLP-1 drugs prevent type 2 diabetes?
In this study of more than 256,000 adults with prediabetes and obesity, people taking GLP-1 drugs had a 31% lower risk of developing type 2 diabetes over three years than people taking metformin, and a 50% higher chance of their blood sugar returning to normal. But the study was observational, not a randomised trial, and the full peer-reviewed paper is still pending — so doctors describe this as strong evidence, not proof. The drugs are not currently approved specifically for prediabetes.
Are GLP-1 drugs better than metformin for prediabetes?
In this particular study, yes — on every outcome measured over three years, including diabetes risk, blood sugar reversal, heart attacks, strokes, heart failure and deaths from any cause. But metformin is cheaper, has decades of safety data, and works well for many people. Which medicine suits a particular person depends on their health, their other conditions, and their doctor's judgement. Never switch medicines based on a news report alone.
Can prediabetes be reversed?
Yes, blood sugar can return to the normal range — the study found the GLP-1 group was 50% more likely to achieve this than the metformin group over three years. Weight loss, healthy eating and regular walking also help blood sugar return to normal. Reversal needs to be maintained with ongoing healthy habits and regular testing, because blood sugar can rise again.
Should I ask my doctor about GLP-1 drugs if I have prediabetes?
It is always reasonable to ask your doctor a question — that is what they are there for. Bring your latest blood sugar results, a list of medicines you take, and your questions about benefits, side effects and cost. Your doctor can weigh whether a GLP-1 drug, metformin, lifestyle change, or a combination is right for you. Do not start, stop or change any medication without that conversation.
The glp-1 drugs prevent type 2 diabetes study 2026 is a strong signal that early, effective treatment matters — and that the years spent in prediabetes are not wasted time, but a window of opportunity. Whether that window is used with lifestyle change, metformin, a GLP-1 drug, or a combination of all three, the best moment to act is now, while blood sugar is still in the range where reversal is possible. Get tested, know your number, and take the next step with your doctor beside you.